HER2-positive breast cancer with invasive micropapillary carcinoma component shows immunosuppressive microenvironment and resistance to neoadjuvant therapy

QR Code

HER2-positive breast cancer with invasive micropapillary carcinoma component shows immunosuppressive microenvironment and resistance to neoadjuvant therapy

BackgroundInvasive micropapillary carcinoma (IMPC) is a rare histopathological subtype of breast cancer (BC) that shows a high incidence of human epidermal growth factor receptor 2 (HER2)-positive expression. However, the therapeutic efficacy of current standard anti-HER2 therapies for this distinct...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lulu Zhang, Lijia Zhou, Anli Yang, Shaoquan Zheng, Keming Chen, Yutian Zou, Qingru Zhou, Daining Wang, Fei Xu, Jiajia Huang, Zhongyu Yuan, Shusen Wang, Yanxia Shi, Peng Sun, Xin An
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Immunology
Subjects:	HER-2 positive invasive micropapillary carcinoma resistance to neoadjuvant therapy immunosuppressive tumor microenvironment CTNNB1 β-catenin
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1623675/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Proteomics‐Empowered Microfluidic‐SERS Immunoassay for Identifying and Detecting Biomarkers of Micropapillary Lung Adenocarcinoma
by: Dechun Zhang, et al.
Published: (2025-07-01)

A Clinical–Radiomics Nomogram for the Preoperative Prediction of Aggressive Micropapillary and a Solid Pattern in Lung Adenocarcinoma
by: Xiangyu Xie, et al.
Published: (2025-05-01)

Genotypic, functional, and phenotypic characterization in CTNNB1 neurodevelopmental syndrome
by: Nina Žakelj, et al.
Published: (2025-10-01)

CTNNB1 syndrome (<i>CTNNB1</i>-NDD) in a child with cerebral palsy: a case report
by: G. S. Golosnaya, et al.
Published: (2023-06-01)

Unravelling genetic etiology of cerebral palsy: findings from a Slovenian pediatric cohort
by: Ula Arkar Silan, et al.
Published: (2025-07-01)

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
by: V. F. Semiglazov, et al.
Published: (2024-11-01)

ALKBH5 Promotes Breast Cancer Stemness Through Regulating Wnt/&beta;-Catenin Signaling
by: Wang K, et al.
Published: (2025-06-01)

Cáncer de mama HER2-bajo: una nueva era en terapias dirigidas
by: Benjamín Walbaum, MD, et al.
Published: (2025-05-01)

Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors
by: Fatemah S. Albalawi, et al.
Published: (2025-07-01)

De-escalated neoadjuvant nab-paclitaxel combined with pyrotinib and trastuzumab in intrinsic HER2-enriched breast cancer (NJMU-BC01): a multicenter, single-arm, phase 2 trialResearch in context
by: Hong Pan, et al.
Published: (2025-08-01)

Target therapy in treatment of HER2-positive breast cancer
by: A. S. Belokhvostova, et al.
Published: (2016-02-01)

STUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICE
by: A. N. Stukov, et al.
Published: (2019-11-01)

Immunomorphological specifcity of HER2-low breast cancer
by: I. V. Mikhailov, et al.
Published: (2024-11-01)

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01)

Disulfiram inhibits migration, invasion and epithelial-mesenchymal transition of gastric cancer cells via β-catenin/CTSB pathway
by: XianYi Zhou, et al.
Published: (2025-12-01)

Silver Jubilee of HER2 targeting: a clinical success in breast cancer
by: Jianli Zhao, et al.
Published: (2025-08-01)

Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer
by: Abbey Zidel, et al.
Published: (2025-05-01)

STUDI IN SILICO KOMPLEKS LIGAND-RESEPTOR EUGENOL DAUN BASIL (Ocimum basilicum L.) DENGAN RESEPTOR HER2 PADA NON-SMALL CELL LUNG CANCER (NSCLC) DENGAN KONTROL GEFITINIB
by: Martina Kurnia Rohmah
Published: (2017-09-01)

Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial
by: Mark Hensley, et al.
Published: (2025-07-01)

A novel bispecific aptamer targeting LAG3 and HER2 enhances T cell-mediated immunotherapy against HER2-positive cancer cells
by: Rui Guo, et al.
Published: (2025-07-01)

Prevalence and Clinicopathologic Features of HER2 Overexpression in Endocervical Adenocarcinoma
by: Niusha Momeni, et al.
Published: (2025-07-01)

HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN GASTRIC CANCER (GC) (RESULTS OF THE MULTICENTER CLINICAL TRIAL)
by: H. C. Chung, et al.
Published: (2017-02-01)

CLINICAL CHARACTERISTICS OF BREAST CANCER WITH STEROID RECEPTORS EXPRESSION AND HER2 AMPLIFICATION
by: F. V. Moiseenko, et al.
Published: (2017-02-01)

EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER
by: O. I. Kit, et al.
Published: (2021-05-01)

Unclassified hepatocellular adenoma with beta-catenin mutation: a case report
by: Ryo Muranushi, et al.
Published: (2021-02-01)

HER2 Reactivity Pattern and Association with Various Tumor Factors in Breast Cancer Patients
by: Greeshma Ann George, et al.
Published: (2025-04-01)

Polyethyleneimine-polyethylene glycol copolymer targeted by anti-HER2 nanobody for specific delivery of transcriptionally targeted tBid containing construct
by: Batoul Saqafi, et al.
Published: (2019-12-01)

Developing a predictive model for neoadjuvant therapy in HER2 overexpression breast cancer using multi-parameter MRI radiomics: two-center retrospective study
by: Lingling Wang, et al.
Published: (2025-07-01)

NGS coverage accurately predicts MET and HER2 (ERBB2) gene amplifications in a real-world non-small cell lung cancer cohort
by: Adam Kowalewski, et al.
Published: (2025-07-01)

Trastuzumab deruxtecan for the late lines of treatment for HER2-low metastatic breast cancer: a clinical case
by: R. A. Murashko, et al.
Published: (2025-03-01)

Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
by: K. R. Zeinalova, et al.
Published: (2014-07-01)

Clinical and morphological aspects of neoadjuvant chemotherapy efficacy in patients with aggressive luminal HER2-negative breast cancer
by: D. A. Morozov, et al.
Published: (2022-01-01)

Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy
by: Rumeysa Colak, et al.
Published: (2025-06-01)

Long-term survival after multidisciplinary treatments for HER2-positive advanced gastric cancer with multiple liver and lung metastases
by: Satoshi Yoshioka, et al.
Published: (2023-08-01)

The Wnt signaling pathway: prospects for pharmacological regulation
by: V. V. Tatarskiy
Published: (2016-04-01)

Key studies that have changed the history and treatment of early HER2+ breast cancer: focus on individual therapy
by: I. V. Kolyadina, et al.
Published: (2021-01-01)

Successful subtotal gastrectomy and hepatectomy for HER2-positive gastric cancer with liver metastasis after trastuzumab-based chemotherapy: a case report
by: Yuki Hirase, et al.
Published: (2024-03-01)

Clinicopathological Profile Of Her2 Positive (Non-Luminal) Breast Cancer Subtype At Haji Adam Malik General Hospital From 2020-2021
by: Yosua Natanael, et al.
Published: (2024-01-01)

Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma
by: Michael Kim, et al.
Published: (2025-08-01)

Targeting PGK1 as a Novel strategy to regulate the sensitivity of HER2 positive gastric cancer to lapatinib
by: Xiaochen Ni, et al.
Published: (2025-07-01)